Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edward A Weinstein

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Antimicrobial Agents and Chemotherapy|March 4, 2020
Assessing Animal Models of Bacterial Pneumonia Used in Investigational New Drug Applications for the Treatment of Bacterial PneumoniaUrsula Waack, Edward A Weinstein, John J Farley
Clinical Pharmacology and Therapeutics|July 6, 2022
Cefiderocol Dosing for Patients Receiving Continuous Renal Replacement TherapyXiaohui Wei, Shabnam Naseer, Edward A Weinstein, et al.
Nuclear Medicine and Biology|September 8, 2014
Nuclear imaging: a powerful novel approach for tuberculosisDaniel H Johnson, Laura E Via, Peter Kim, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 16, 2005
Inhibitors of type II NADH:menaquinone oxidoreductase represent a class of antitubercular drugsEdward A Weinstein, Takahiro Yano, Lin-Sheng Li, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 4, 2021
US Food and Drug Administration (FDA): Benefit-Risk Considerations for Cefiderocol (Fetroja®)Shabnam Naseer, Edward A Weinstein, Daniel B Rubin, et al.
Science Translational Medicine|October 24, 2014
Imaging Enterobacteriaceae infection in vivo with 18F-fluorodeoxysorbitol positron emission tomographyEdward A Weinstein, Alvaro A Ordonez, Vincent P DeMarco, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 17, 2016
A Systematic Approach for Developing Bacteria-Specific Imaging TracersAlvaro A Ordonez, Edward A Weinstein, Lauren E Bambarger, et al.
Antimicrobial Agents and Chemotherapy|August 25, 2019
Erratum for DeMarco et al., "Determination of [<sup>11</sup>C]Rifampin Pharmacokinetics within Mycobacterium tuberculosis-Infected Mice by Using Dynamic Positron Emission Tomography Bioimaging"Vincent P DeMarco, Alvaro A Ordonez, Mariah Klunk, et al.
Antimicrobial Agents and Chemotherapy|July 15, 2015
Determination of [11C]rifampin pharmacokinetics within Mycobacterium tuberculosis-infected mice by using dynamic positron emission tomography bioimagingVincent P DeMarco, Alvaro A Ordonez, Mariah Klunk, et al.
ACS Infectious Diseases|August 2, 2018
Positron Emission Tomography Imaging with 2-[<sup>18</sup>F]F- p-Aminobenzoic Acid Detects Staphylococcus aureus Infections and Monitors Drug ResponseZhuo Zhang, Alvaro A Ordonez, Hui Wang, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Antimicrobial Agents and Chemotherapy|March 4, 2020
Assessing Animal Models of Bacterial Pneumonia Used in Investigational New Drug Applications for the Treatment of Bacterial PneumoniaUrsula Waack, Edward A Weinstein, John J Farley
Clinical Pharmacology and Therapeutics|July 6, 2022
Cefiderocol Dosing for Patients Receiving Continuous Renal Replacement TherapyXiaohui Wei, Shabnam Naseer, Edward A Weinstein, et al.
Nuclear Medicine and Biology|September 8, 2014
Nuclear imaging: a powerful novel approach for tuberculosisDaniel H Johnson, Laura E Via, Peter Kim, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 16, 2005
Inhibitors of type II NADH:menaquinone oxidoreductase represent a class of antitubercular drugsEdward A Weinstein, Takahiro Yano, Lin-Sheng Li, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 4, 2021
US Food and Drug Administration (FDA): Benefit-Risk Considerations for Cefiderocol (Fetroja®)Shabnam Naseer, Edward A Weinstein, Daniel B Rubin, et al.
Science Translational Medicine|October 24, 2014
Imaging Enterobacteriaceae infection in vivo with 18F-fluorodeoxysorbitol positron emission tomographyEdward A Weinstein, Alvaro A Ordonez, Vincent P DeMarco, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 17, 2016
A Systematic Approach for Developing Bacteria-Specific Imaging TracersAlvaro A Ordonez, Edward A Weinstein, Lauren E Bambarger, et al.
Antimicrobial Agents and Chemotherapy|August 25, 2019
Erratum for DeMarco et al., "Determination of [<sup>11</sup>C]Rifampin Pharmacokinetics within Mycobacterium tuberculosis-Infected Mice by Using Dynamic Positron Emission Tomography Bioimaging"Vincent P DeMarco, Alvaro A Ordonez, Mariah Klunk, et al.
Antimicrobial Agents and Chemotherapy|July 15, 2015
Determination of [11C]rifampin pharmacokinetics within Mycobacterium tuberculosis-infected mice by using dynamic positron emission tomography bioimagingVincent P DeMarco, Alvaro A Ordonez, Mariah Klunk, et al.
ACS Infectious Diseases|August 2, 2018
Positron Emission Tomography Imaging with 2-[<sup>18</sup>F]F- p-Aminobenzoic Acid Detects Staphylococcus aureus Infections and Monitors Drug ResponseZhuo Zhang, Alvaro A Ordonez, Hui Wang, et al.
Pageof 2